Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
An episode of defibrination with bleeding following high dose Edinburgh Factor IX (D.E.F.IX) replacement in a patient with haemophilia B undergoing knee joint replacement is reported. We have also monitored plasma fibrinopeptide A levels in patients with haemophilia B following ten standard doses of D.E.F.IX (15-20 u/kg) and have been unable to document any change. Activation of the coagulation system, as previously noted, appears to be related to the use of Factor IX concentrates in high doses.
D000328:Adult; D001777:Blood Coagulation; D004211:Disseminated Intravascular Coagulation / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D005164:Factor IX / Q000009:adverse effects* / Q000627:therapeutic use; D005344:Fibrinopeptide A / Q000032:analysis; D002836:Hemophilia B / Q000628:therapy; D006801:Humans; D008297:Male
D005344:Fibrinopeptide A; D005164:Factor IX